EFFICACY OF INTRAVENOUS IMMUNOGLOBULIN ALONE ON CORONARY 1 **ARTERY LESION REDUCTION IN KAWASAKI DISEASE** 2

- 3
- Ho-Chang Kuo MD PhD^{1 2 3#*}; Ming-Chih Lin MD PhD^{4-8#}; Chung-Chih Kao,MD^{9#}; Ken-4
- 5
- Pen Weng MD^{10#}; Yun Ding PhD^{11#}; Chih-Jung Chen MD PhD^{1,12,13}; Sheng-Ling Jan MD PhD¹⁴⁻¹⁶; Kuang-Jen Chien MD¹⁰; Chun-Hsiang Ko MS⁹; Chien-Yu Lin MD¹⁷; Wei-Te Lei MD¹⁷; Ling-Sai Chang MD^{1,2}; Mindy Ming-Huey Guo MD^{1, 2}; Kuender D. Yang MD 6
- 7
- PhD¹⁸; Karl G. Sylvester PhD¹¹; Zhi Han PhD¹¹; John C. Whitin PhD¹¹; Lu Tian PhD¹¹; 8 Henry Chubb MD¹¹; Scott R. Ceresnak MD¹¹; Doff McElhinney MD¹¹; Harvey J. Cohen 9
- MD¹¹; Xuefeng B. Ling PhD¹¹* 10
- 1. College of Medicine Chang Gung University Taoyuan Taiwan 33302 11
- 2. Kawasaki Disease Center and Department of Pediatrics Kaohsiung Chang Gung 12
- Memorial Hospital and Chang Gung University College of Medicine Kaohsiung Taiwan 13
- 83301 14
- 3. Department of Respiratory Therapy Kaohsiung Chang Gung Memorial Hospital 15
- 16 Kaohsiung Taiwan 83301
- 17 Department of Post-Baccalaureate Medicine College of Medicine National Chung Hsing University Taiwan. 18
- 5. Children's Medical Center Taichung Veterans General Hospital Taichung Taiwan. 19
- 20 6. School of Medicine National Yang Ming Chiao Tung University Taipei Taiwan.
- 7. Department of Food and Nutrition Providence University Taichung Taiwan. 21
- 22 8. School of Medicine Chung Shan Medical University Taichung Taiwan.
- 9. Department of Pediatric Cardiology Tungs' Taichung Metro Harbor Hospital Taiwan. 23
- 10. Congenital Structural Heart Disease Center Department of Pediatrics Kaohsiung 24
- Veterans General Hospital Kaohsiung Taiwan 813414 25
- 11. School of Medicine Stanford University Stanford 94301 USA 26
- 12. Division of Pediatric Infectious Diseases Departments of Pediatrics Chang Gung 27 Memorial Hospital Taoyuan Taiwan 333 28
- 29 13. Molecular Infectious Diseases Research Center Chang Gung Memorial Hospital 333 Taoyuan Taiwan 30
- 14. Department of Pediatrics Children's Medical Center Taichung Veterans General 31 Hospital Taichung Taiwan 32
- 15. Department of Pediatrics School of Medicine National Yang Ming Chiao Tung 33 University Taipei Taiwan. 34
- 16. Department of Pediatrics School of Medicine Kaohsiung Medical University 35 Kaohsiung Taiwan. 36

- 17. Section of Immunology Rheumatology and Allergy Department of Pediatrics Hsinchu
 Mackay Memorial Hospital Hsinchu Taiwan.
- 18. MacKay Children's Hospital Taipei Taiwan.
- 40
- 41 # Ho-Chang Kuo, Ming-Chih Lin, Chung-Chih Kao, Ken-Pen Weng, Yun Ding have
- 42 equal contribution in this work as co-first authors.
- 43
- 44 (email address: Ming-Chih Lin mingclin@gmail.com; Chung-Chih Kao
- 45 cckao2cv@yahoo.com; Ken-Pen Weng kenpenweng@yahoo.com.tw; Yun Ding
- dingy1979@gmail.com; Chih-Jung Chen james.ped@gmail.com; Sheng-Ling Jan
- 47 sljan@vghtc.gov.tw; Kuang-Jen Chien kjchien@vghks.gov.tw; Chun-Hsiang Ko
- 48 adamker01@gmail.com; Chien-Yu Lin mmhped.lin@gmail.com; Wei-Te Lei
- 49 weite.lei@gmail.com ; Ling-Sai Chang joycejohnsyoko@gmail.com; Mindy Ming-Huey
- 50 Guo mindymhguo@cgmh.org.tw; Kuender D. Yang yangkd.yeh@gmail.com; Ho-Chang
- 51 Kuo erickuo48@yahoo.com.tw; Karl G. Sylvester karls@stanford.edu; Zhi Han
- 52 zhihan01@stanford.edu; Lu Tian lutian@stanford.edu; Henry Chubb
- 53 mhchubb@stanford.edu; Scott R. Ceresnak ceresnak@stanford.edu; Doff McElhinney
- ⁵⁴ doff@stanford.edu; John C. Whtin cuke@stanford.edu; Harvey J. Cohen
- 55 punko@stanford.edu; Xuefeng B. Ling bxling@stanford.edu)
- 56
- 57 Corresponding Authors:
- 58 Ho-Chang Kuo MD PhD, Kawasaki Disease Center and Department of Pediatrics
- 59 Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of 60 Medicine Kaohsiung Taiwan (erickuo48@yahoo.com.tw)
- 51 Xuefeng B. Ling PhD, School of Medicine Stanford University Stanford, USA
- 62 (bxling@stanford.edu)
- 63 64
- 65
- 66
- -
- 67
- 68
- 69
- 70
- 71

72 What is New?

73	This study represents the first multi-center randomized controlled trial
74	investigating the efficacy of high-dose aspirin or intravenous immunoglobulin
75	(IVIG) during the acute stage of KD. This study assessed the impact of
76	discontinuing high-dose aspirin (80–100 mg/kg/day) on the occurrence of CAL
77	during the acute phase treatment of Kawasaki Disease.
78	No significant differences were observed between high-dose aspirin plus IVIG
79	treatment and IVIG alone treatment in terms of the frequency of abnormal
80	coronary artery abnormalities. Additionally, our analysis revealed no statistically
81	significant differences in either the treatment effect (the number of cases
82	successfully treated) or prevention effect (the prevention of new cases) between
83	these two treatments.
84	What Are the Clinical Implications?
84 85	What Are the Clinical Implications?Comparison analysis indicated the non-inferiority between two groups with or
	·
85	 Comparison analysis indicated the non-inferiority between two groups with or
85 86	 Comparison analysis indicated the non-inferiority between two groups with or without high-dose aspirin.
85 86 87	 Comparison analysis indicated the non-inferiority between two groups with or without high-dose aspirin. Administering the standard 2 g/kg/day IVIG without high-dose aspirin (80–100)
85 86 87 88	 Comparison analysis indicated the non-inferiority between two groups with or without high-dose aspirin. Administering the standard 2 g/kg/day IVIG without high-dose aspirin (80–100 mg/kg/day) during the acute phase therapy for KD does not increase the risk of
85 86 87 88 89	 Comparison analysis indicated the non-inferiority between two groups with or without high-dose aspirin. Administering the standard 2 g/kg/day IVIG without high-dose aspirin (80–100 mg/kg/day) during the acute phase therapy for KD does not increase the risk of coronary artery lesions, which are a primary cause of morbidity and mortality in
85 86 87 88 89 90	 Comparison analysis indicated the non-inferiority between two groups with or without high-dose aspirin. Administering the standard 2 g/kg/day IVIG without high-dose aspirin (80–100 mg/kg/day) during the acute phase therapy for KD does not increase the risk of coronary artery lesions, which are a primary cause of morbidity and mortality in KD patients.
85 86 87 88 89 90 91	 Comparison analysis indicated the non-inferiority between two groups with or without high-dose aspirin. Administering the standard 2 g/kg/day IVIG without high-dose aspirin (80–100 mg/kg/day) during the acute phase therapy for KD does not increase the risk of coronary artery lesions, which are a primary cause of morbidity and mortality in KD patients. Addition of high-dose aspirin during initial IVIG treatment is not statistically

95 ABSTRACT

Background: Though Aspirin and intravenous immunoglobulin (IVIG) remain the
standard treatments for Kawasaki Disease (KD) to minimize coronary artery damage,
the duration and dosage of aspirin are inconsistent across hospitals. However, the lack
of multi-center randomized trials prevents definitive answers to the impact of high-dose
aspirin.

101 Methods This clinical trial was structured as a prospective, evaluator-blinded, multi-

102 center randomized controlled trial with two parallel arms, aiming to assess the

103 effectiveness of IVIG as a standalone primary therapy of KD in comparison to the

104 combination of IVIG with high-dose aspirin therapy. KD patients were enrolled between

105 September, 2016 and August, 2019. A final cohort of 134 patients were randomly

assigned to the standard and test groups with 69 and 65 patients, respectively. The

107 Standard group received IVIG (2 g/kg) along with aspirin (80-100 mg/kg/day) until fever

subsided for 48 hours. The test group received IVIG (2 g/kg) alone. Following the initial

treatment, both groups received a daily aspirin dose (3-5 mg/kg) for six weeks. The

primary outcome measure was the occurrence of coronary artery lesions (CAL) at the 6-

111 8 weeks mark. The secondary outcome is IVIG resistance.

Results The overall rate of CAL in test group decreased from 10.8% at diagnosis to 1.5% and 3.1% at 6 weeks and 6 months, respectively. The CAL rate of standard group declined from 13.0% to 2.9% and 1.4%, with no statistically significant difference (P>0.1) in the frequency of CAL between the two groups. Furthermore, no statistically significant differences were found for treatment (P>0.1) and prevention (P>0.1) effect between the two groups.

118	Conclusions: This marks the first prospective multi-center randomized controlled trial
119	comparing the standard treatment of KD using IVIG plus high-dose aspirin against IVIG
120	alone. Our analysis indicates that addition of high-dose aspirin during initial IVIG
121	treatment is neither statistically significant nor clinically meaningful for CAL reduction.
122 123	Registration URL: http://www.clinicaltrials.gov; identifier: NCT02951234
124	
125	
126	
127	
128	
129	
130	
131	
132	
133	
134	
135	
136	
137	
138	
139	
140	
141	
142	
143	
144	
145	

146 Introduction

147	Kawasaki disease (KD) is an acute vasculitis characterized by self-limiting tendencies,
148	predominantly impacting medium-sized vessels and resulting in coronary artery lesions ^{1,}
149	² such as dilatations, fistulas, infarctions ³ and aneurysms ⁴ . Initial treatment typically
150	includes intravenous immunoglobulin (IVIG) and high-dose aspirin (80–100 mg/kg/day),
151	which synergistically exert anti-inflammatory effects according to the American Heart
152	Association (AHA) criteria. It's noteworthy that high-dose aspirin, with its anti-
153	inflammatory properties, primarily addresses inflammation, while lower doses are
154	primarily directed at thrombosis.
155	The commonly accepted understanding of CAL, also known as coronary artery
156	abnormalities (CAA), is based on diagnostic criteria set by the Japanese Ministry of
157	Health. These criteria involve a maximum internal diameter exceeding 3 mm in children
158	under 5 years old or exceeding 4 mm in children aged 5 years and above. Furthermore,
159	the criteria encompass the presence of luminal irregularity, a segmental lumen 1.5 times
160	larger than an adjacent one, or a visibly irregular luminal contour with a Z score
161	exceeding 2.5 standard deviations ⁵⁻¹¹ . In our previous investigations, which involved a
162	sequential assessment of coronary artery lesions in 341 Taiwanese children with
163	Kawasaki disease ¹² , we found that 35% of KD patients experienced dilatation during the
164	acute phase, 17.2% one month after the disease onset, and 10.2% during the two-
165	month follow-up. Additionally, 4% showed persistent coronary artery lesions lasting for
166	over one year.

Studies suggest that administering intravenous IVIG at a dose of 2 g/kg/day is highly
 successful in minimizing the likelihood of CAA in individuals with Kawasaki disease¹³⁻¹⁶.

The approved therapy for the acute phase of Kawasaki disease, as recommended by 169 the American Heart Association (AHA) and the American Academy of Pediatrics (AAP), 170 includes the administration of IVIG with a single 2 g/kg dose given over 10-12 hours. 171 along with oral high-dose aspirin at 80-100 mg/kg/day¹⁷. Although aspirin demonstrates 172 notable anti-inflammatory effects in high doses and anti-platelet effects in low doses, 173 there is no prospective study validating its role in diminishing the formation of CAL. 174 According to two meta-analyses, high-dose aspirin alone does not effectively reduce the 175 risk of CAA in KD; the reduction is predominantly reliant on the dose of IVIG^{18, 19}. 176 Several studies propose a strong correlation between the incidence of CAL and the 177 dose of IVIG, indicating that the dosage of aspirin may not have a significant influence. 178 This suggests that anti-platelet aspirin doses alone might be sufficient during the acute 179 phase of KD. In a study by Hsieh et al., it was discovered that administering high-dose 180 aspirin during the acute stage of KD did not affect the response rate to IVIG therapy, the 181 duration of fever, or the occurrence of CAL when children were treated with a high IVIG 182 dose (2 g/kg) in a single infusion¹³. In our retrospective analysis, which included 851 KD 183 patients from two medical centers in Taiwan, we found no noteworthy distinctions 184 between groups (with or without high-dose aspirin) with regard to gender, IVIG 185 resistance, CAL formation, and the duration of hospitalization¹⁶. These retrospective 186 findings imply that aspirin may offer minimal to no extra advantages when combined 187 with IVIG therapy during the acute phase of KD. 188

At present, there is a shortage of well-conducted randomized controlled trials (RCTs) that can determine whether high-dose aspirin should continue to be a fundamental element of the treatment protocol for children diagnosed with KD. Furusho et al.

conducted a study comparing the efficacy of IVIG and aspirin treatment against aspirin 192 used alone in conjunction with IVIG²⁰. According to Sanati et al., the use of high-dose 193 aspirin does not have a substantial impact on preventing CAA in KD. In a prospective 194 open-label trial conducted at a single site, administering the standard 2 g/kg/day IVIG 195 without high-dose aspirin during acute-stage therapy did not elevate the risk of CAL in 196 62 patients with both typical and atypical KD²¹. Terai et al. discovered that the frequency 197 of coronary abnormalities in KD was not affected by the aspirin dosage¹⁹. Furthermore, 198 Chiang et al. performed a meta-analysis encompassing nine cohorts and a total of 199 200 12,182 children. The findings indicate that prescribing low-dose or omitting aspirin during the acute stage of KD might be linked to a lower occurrence of CAL²². 201 The risk associated with aspirin therapy in children with KD is generally considered low 202 and appears to be comparable to risks reported in other situations. However, 203 documented cases exist of severe side effects associated with aspirin in children 204 undergoing KD treatment^{16, 23-25}. Given the potential risks of drug toxicity and the limited 205 robust evidence supporting the prevention of CAL formation, there is a necessity to 206 reevaluate the role of high-dose aspirin during the acute stage of KD. To address this 207 208 concern, we conducted a multi-center, prospective, parallel-group, open-label, noninferiority randomized controlled trial to investigate whether high-dose aspirin, 209 210 administered during the acute stage of KD, has beneficial effects in preventing the formation of CAL. 211

A recent investigative study, exploring the heterogeneity of Kawasaki disease, identified four unique patient clusters. These clusters were delineated according to subjective clinical features and laboratory results, resulting in the formation of the liver subgroup,

215	band subgroup, node subgroup, and young subgroup ²⁶ . It is noteworthy that these
216	subgroups exhibited differences in their response to treatment and the outcomes of the
217	disease, including the risk of coronary artery aneurysm and the rate of intravenous
218	immunoglobulin resistance. Therefore, in this trial, an approach considering of these
219	subgroups, following the recent proposal by the UCSD Burns group
220	(liver/band/node/young), was also implemented. The goal was to compare the treatment
221	effectiveness for each subgroup of Kawasaki disease between the standard and test
222	arms, respectively.
223	
224	
225	
226	
227	
228	
229	

242 Methods

Overall Study design: This study has been structured as a multi-center, prospective, 243 randomized controlled, evaluator-blinded, non-inferiority trial with two parallel groups. 244 The aim is to evaluate the effectiveness of intravenous immunoglobulin (IVIG) alone in 245 246 comparison to IVIG combined with high-dose aspirin (80-100 mg/kg/day) as the primary treatment for Kawasaki disease (KD) during the acute stage. The clinical trial was 247 conducted at five medical centers in Taiwan. Individuals under the age of 18 meeting 248 the criteria for KD set by the American Heart Association (AHA) were eligible for 249 enrollment in this study. Individuals with a fever of more than 10 days, previous 250 treatment of steroids, biologics or were excluded. All patients were administered a high 251 dose of intravenous immunoglobulin (IVIG) at 2 g/kg over a 12-hour duration, either with 252 high-dose aspirin (80-100mg/kg/day) in group 1 (standard group) or without aspirin in 253 group 2 (test group). Following the resolution of fever, low-dose aspirin (3-5 mg/kg/day) 254 was prescribed for all KD patients for a period of 6-8 weeks or until normal 255 echocardiography and inflammation laboratory data, in accordance with the guidelines 256 provided by the AHA. The primary endpoint was identified as the formation of CAL at 6-257 8 weeks after enrollment. 258

This study was approved by the Institutional Review Board (IRB) at each site of the participating institutions, including Linkou Chang Gung Memorial Hospital, Kaohsiung Chang Gung Memorial Hospital, Taichung Veterans General Hospital, Kaohsiung Veterans General Hospital, and Tungs' Taichung Metro Harbor Hospital. Informed consent form (ICF) were signed by the patient or a legal guardian.

264	NCT registration: The study was registered at ClinicalTrials.gov with Identifier:
265	NCT02951234 and Release Date: November 3 2016.
266	Statistics method: All baseline characteristics were utilized to assess the
267	comparability of both arms of the trial. The primary outcome evaluation and safety
268	assessment were conducted using the intention-to-treat (ITT) population. Continuous
269	variables, including age, gender, hospitalization duration (days), fever duration (days),
270	height, weight, and clinical manifestations, were presented using either the mean \pm
271	standard deviation or frequency tables. Data analysis involved the use of the Chi-square
272	test, independent t -test, Generalized Estimating Equation Model, and repeated
273	measure analysis of variance (ANOVA) and non-inferiority comparison. The
274	predetermined two-sided significance level for all statistical tests and confidence
275	intervals was set at 5%.
276	
277	
278	
279	
280	
281	
282	
283	
284	

285 **Results**

286 Patient enrollment and experimental design for the clinical trial

In this investigation, 152 patients diagnosed with Kawasaki Disease (KD) were enrolled 287 (refer to Figure 1 for the enrollment flowchart). Participants were recruited from five 288 medical centers in Taiwan. After excluding 18 cases, which included atypical KD cases 289 290 or cases without completion of the study protocol, a final cohort of 134 KD patients was selected for further analysis. The schematic trial design is presented in supplementary 291 Figure 1. The overall comparison between the test and standard groups is illustrated in 292 supplementary Figure 1A: 69 patients were allocated to the standard group, receiving 293 the standard treatment of intravenous immunoglobulin (2 g/kg) along with aspirin (80-294 295 100 mg/kg/day) until their fever subsided for 48 hours. The remaining 65 patients were assigned to the test group, receiving intravenous immunoglobulin (2 g/kg) alone. 296 Majority of the fever was resolved within 24 hrs between the two groups after IVIG 297 treatment. Following the initial treatment, both groups received a daily aspirin dose (3-5 298 mg/kg) for six weeks. The primary endpoint of this trial is the development of coronary 299 artery lesions (CAL). Patients underwent 2D echocardiography at baseline, weeks 1, 2, 300 4, and 6-8, and again at 6 months. At 6 weeks and 6 months, the internal diameter and 301 Z-score of the left and right main coronary arteries were calculated. CAL was defined for 302 each age group: over 3.0 mm diameter for children under 5 years, over 4.0 mm for 303 those 5 years or older, or any irregular luminal contour or Z-score exceeding 2.5. 304 Throughout the study period, we also compared the treatment effect and prevention 305 306 effect, as shown in supplementary Figure 1B and 1C, respectively. For the treatment effect, we followed CAL patients (Z score >2.5) at the acute phase to the endpoint. For 307

the prevention effect, we followed non-CAL patients (Z score ≤ 2.5) at the acute phase to the endpoint.

310 Baseline Characteristics and Group Distribution of Participants in the Study

The percentage of males in the standard group (43%, n=30) and the test group (39%,

n=25) did not exhibit a significant difference (P=0.933). Similarly, no statistically

313 significant distinctions were observed between the groups in terms of mean weight

(P=0.986) or height (P=0.969). Likewise, the mean ages of the two groups were

comparable (P=0.464). Further analysis revealed no significant differences in baseline

316 characteristics between the standard and test groups. Specifically, admission days

317 (P=0.224), white blood cell counts (P=0.053), hemoglobin levels (P=0.138), platelet

counts (P=0.074), GOT levels (P=0.668), and GPT levels (P=0.842) were all similar

between the groups. The standard group exhibited significantly higher C-reactive

protein levels at baseline compared to the test group (68.09 ± 76.66 vs. 41.86 ± 48.06

321 mg/L, P=0.021). Baseline coronary artery diameters and Z-scores in both the left main

322 coronary artery (LMCA), right coronary artery (RCA), and left anterior descending artery

(LAD) did not show significant differences between the groups (P=0.380, P=0.281, and

³²⁴ P=0.788 for diameter; P=0.380, P=0.279, and P=0.674 for Z-score) (Table 1).

325 Clinical Parameters Changes and Dynamics During the Study Period

Throughout the study, there was a noticeable decrease in C-reactive protein (CRP)

levels. Starting from an average baseline of 55.47 mg/L (±65.60 SD), they decreased to
 just 1.76 mg/L (±8.34 SD) after 6 weeks. Although statistical analysis initially revealed a

significant difference between the standard and test groups at baseline (P=0.029), this

distinction disappeared by the 6-week mark (P=0.939). Overall, CRP levels exhibited a

significant decline across the study duration (P<0.001), and interestingly, the specific 331 pattern of this decline showed slight differences between the two groups (P=0.031 for 332 interaction effect). Both groups demonstrated a general increase in the average platelet 333 count after IVIG treatment compared to baseline levels. While the average platelet 334 count changed significantly over time (P=0.001), there were no noticeable differences 335 336 between the two groups at either baseline (P=0.359) or 6 weeks after treatment (P=0.667), and no interaction effect was observed between time and group type 337 338 (P=0.123).

While white blood cell (WBC) levels exhibited a significant difference between the 339 standard and test groups at baseline (P=0.035), this distinction disappeared by the 6th 340 week (P=0.336). Overall, WBC levels displayed a significant decrease across the study 341 duration (P<0.001), but the rate of decrease did not show a significant difference 342 between the two groups (P=0.226). Hemoglobin levels increased significantly after 6 343 weeks in both groups (P<0.001). Although baseline levels differed significantly between 344 the groups (P=0.020), this difference vanished by the 6th week (P=0.102). The rate of 345 increase did not exhibit a significant difference between the groups (P=0.874). Two liver 346 347 enzymes, glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT), were monitored over time. Both enzymes showed a significant decrease 348 throughout the study (P<0.001). Interestingly, their levels at baseline and after 6 weeks 349 350 did not display a significant difference between the two groups (P=0.686 for GOT and P=0.809 for GPT), and the rate of decrease over time was also similar (P=0.704 for 351 GOT and P=0.842 for GPT). 352

353 Coronary Artery Changes and Frequency during study period

The diameter of the left main coronary artery (LMCA) significantly decreased across the 354 study in both groups (p < 0.001), starting at 2.20 mm and reducing to 2.02 mm after 6 355 months. The rate of reduction was similar between the groups at each time point 356 (P=0.904 for baseline, P=0.479 for 6th week, and P=0.096 for 6th month), and there 357 was no significant interaction effect between time and groups (P=0.172). Similarly, the 358 359 left anterior descending artery (LAD) exhibited a significant narrowing in both groups (p < 0.001), starting at 1.75 mm and decreasing to 1.56 mm after 6 months. Once again, 360 the pattern of reduction was comparable between the groups (P=0.188 for baseline, 361 362 P=0.582 for 6th week, and P=0.138 for 6th month). However, no interaction effect was observed between time and groups (P=0.675). Likewise, the right coronary artery (RCA) 363 narrowed significantly over time (P = 0.006), from 1.91 mm to 1.81 mm after 6 months, 364 with no noticeable differences in the rate of reduction between the groups (P=0.162 for 365 baseline, P=0.754 for 6th week, and P=0.290 for 6th month), and there was no 366 significant interaction between time and RCA in the groups (P=0.827). 367 Overall, at baseline, 10.8% of patients in the test group and 13.0% in the standard 368 group presented abnormal coronary artery diameter (Z score >2.5) in at least one of the 369 370 three coronary arteries. By the 6th month, these percentages reduced to 3.1% and 1.4%, respectively. No significant differences were observed between the groups 371 regarding the frequency of coronary artery abnormalities during the study period (P = 372 373 0.529). The frequency of coronary artery lesions exhibited a significant decrease compared to the baseline, starting from the 6th week (P=0.002) through the end of the 374 study period (6th month P=0.002). Similarly, no significant differences were observed 375

between the two groups on either LMCA or RCA (detailed analysis in the supplementaryappendix).

378 As for the non-inferiority comparison between the two groups, we consider a difference 379 in CAL rate of 10% or less as clinically insignificant and the noninferiority margin was set at 10%. The CAL rate was 12.3% (8/65; 95% confidence interval: 5.5% to 22.8%) in 380 381 the test group and 15.9% (11/69; 95% confidence interval: 8.2% to 26.7%) in the standard care group. The one-sided 97.5% confidence interval for the CAL difference 382 between the test and standard care group was [-100%, 8.1%]. The upper end of the 383 confidence interval was below the noninferiority margin of 10%. Therefore, we can 384 conclude with 97.5% confidence that the CAL rate in the test group was no higher than 385 that in the standard care group by 10% and the noninferiority was established in current 386 cohort size of patient numbers in both standard and test groups. 387 In addition to assessing CAL as the primary outcome, we also investigated IVIG 388 resistance as a secondary outcome. Table S1 indicates that both groups had 3 patients 389 each with IVIG resistance. There were no significant differences in the rates of IVIG 390

resistance between the groups (P=0.940).

Treatment and Prevention Effect on Coronary Artery Changes and Frequency

393 during Study Period between Two Groups

Throughout the study duration, we noted that most CAL cases were detected during the acute phase. However, some patients were initially normal during the acute phase but later developed CAL at 6 weeks or 6 months, even after receiving IVIG or IVIG plus high-dose treatment. To compare the treatment effect between the test and standard groups, we conducted statistical analysis of CAL frequency exclusively on the CALpatients identified during the acute phase.

As depicted in Table 4, overall, at the baseline, 10.8% of patients in the test group and

- 401 13.0% in the standard group presented abnormal coronary artery diameter (Z
- score >2.5) in at least one of the three coronary arteries. By the 6th month, all patients
- 403 had recovered from CAL. No significant differences were observed between the groups
- 404 concerning the frequency of abnormal coronary artery abnormalities during the study
- 405 period (P = 0.423). The frequency of coronary artery lesions exhibited a significant
- decrease compared to the baseline, starting from the 6th week (P=0.001) through the
- 407 end of the study period (6th month P<0.001). Similarly, no significant treatment
- differences were observed between the two groups on either LMCA or RCA (detailed
- analysis in the supplementary appendix).
- Following treatment effect, we investigated the preventive impact on the frequency of
- 411 Coronary Artery Lesions (CAL) over the study duration for patients who developed CAL
- 412 later after IVIG or IVIG plus high-dose aspirin treatment. We performed the same
- 413 statistical analysis for the comparison of CAL frequencies, as illustrated in
- 414 Supplementary Table 2. No statistical difference was identified between the standard
- and test groups. However, a minimal number of newly developed CAL cases were
- observed after treatment: 2 in the test group and 1 in the standard group.

417 **Discussion**

Preventing coronary artery lesions (CALs) is crucial as it represents the most severe
complication of Kawasaki disease (KD). Therefore, determining the ideal aspirin dosage
to prevent this complication is of paramount importance. Aspirin, a salicylate drug,

works by inhibiting the production of prostaglandins, which are involved in the
inflammatory response. By exerting anti-inflammatory and antiplatelet effects, aspirin is
thought to play a role in suppressing the inflammatory response and reducing the risk of
blood clots in Kawasaki disease.

Our previous study demonstrated that the use of low-dose aspirin in the initial treatment 425 426 of children with KD was not linked to fever recurrence or the formation of CAL. Additionally administering high-dose aspirin during the acute stage of KD did not yield 427 any benefits in terms of inflammation or improved treatment outcomes¹⁶. This study 428 represents the first multi-center randomized controlled trial investigating the efficacy of 429 high-dose aspirin or intravenous immunoglobulin (IVIG) during the acute stage of KD. In 430 this clinical trial, we assessed the impact of discontinuing high-dose aspirin (80–100 431 mg/kg/day) on the occurrence of CAL during the acute phase treatment of KD in both 432 the test and standard groups. The findings revealed that the elimination of high-dose 433 434 aspirin did not yield a significant effect on CAL incidence. No significant differences were observed between the groups in terms of the frequency of abnormal coronary 435 artery abnormalities during the study period (P = 0.529). Through a statistically robust 436 437 non-inferiority comparison, we concluded with 97.5% confidence that the CAL rate in the test group was not higher than that in the standard care group by 10%, establishing 438 noninferiority with clinical insignificance. 439

Evaluating the overall effectiveness of IVIG treatment entails considering both its treatment effect (the number of cases successfully treated) and prevention effect (the prevention of new cases). Our analysis revealed no statistically significant differences in either the treatment effect (P=0.423) or prevention effect (P>0.999) between these two groups, despite the occurrence of very limited newly developed CAL cases.

Conclusions regarding the prevention effect may require a larger cohort to ensurerobust findings.

Furthermore, we performed an analysis to compare the effectiveness in four subgroups of KD, which were categorized based on subjective clinical features and laboratory results. Within each of these individual clusters or subgroups, encompassing two clusters with distinct characteristics, no significant difference was observed in the reduction of CAL rates at the 6th week or 6th month after treatment during the acute phase between the test and standard groups.

The primary purpose of administering high-dose aspirin was to elicit anti-inflammatory 453 effects. As a result, we conducted an analysis comparing efficacy in subgroups 454 classified based on the acute phase levels of two inflammatory biomarkers: C-reactive 455 456 protein (CRP) and platelet count. Consistent with findings in other subgroups, we identified no significant distinction between the test and standard groups in either the 457 low (normal range) subgroups for CRP or platelet count, nor in the high (abnormal 458 range) subgroups. The analysis of these subgroups indicates that the administration of 459 IVIG treatment alone, without the addition of high-dose aspirin, does not increase the 460 risk of CAL six weeks or later after the initial treatment. Furthermore, this approach has 461 wider relevance for KD patients with varied demographic and clinical characteristics. 462

In conclusion, in our trial, high-dose aspirin does not play a significant role in managing
 coronary artery lesions in KD patients. Administering the standard 2 g/kg/day IVIG
 without high-dose aspirin (80–100 mg/kg/day) during the acute phase therapy for KD

- does not increase the risk of coronary artery lesions, which are a primary cause of
- 467 morbidity and mortality in KD patients. Results from comparison analysis indicate the
- 468 non-inferiority between two groups. Therefore, addition of high-dose aspirin during initial
- 469 IVIG treatment is not statistically significant or clinically meaningful.

470 **Contributors**:

- 471 H-CK, HJC and XBL contributed to the study conception and design. M-CL, C-CK, K-PW, YD,
- 472 ZH, and LT contributed to the statistical analyses, data entry, and verification. All authors were
- involved in the study implementation, data acquisition, and interpretation of the results. All
- 474 authors critically reviewed the manuscript, approved the final version for submission, and agree
- to be accountable for all aspects of this work.

476 **Declaration of interests**

477 All the authors hereby declare to have no financial interests to disclose regarding this article.

478 Data sharing

The data that support the findings of this study are available from the corresponding author on reasonable request. Participant data without names and identifiers will be made available after approval from the corresponding author and Chang Gung Memorial Hospital. After publication of study findings, the data will be available for others to request.

483 Acknowledgements

- 484 The authors thank the patients and their carers who participated in this study. This study
- received funding from the following grants: CMRPG8J1151 CPRPG8F0791 CPRPG8H0051-2
- 486 CMRPG8M1431 CMRPG8M1421 and CMRPG8L1241-2 from Chang Gung Memorial Hospital
- 487 and the NSTC 112-2314-B-182-032-MY3 from National Science and Technology Council of
- 488 Taiwan to Dr. Ho; and 1R41TR004351-01 from US National Institute of Health to Dr. Ling.

- 489 Although these institutes provided financial support, they had no influence on the way in which
- 490 we collected analyzed or interpreted the data or wrote this manuscript.

491 Figure legends

- 492 Figure 1: Consort diagram for patient enrollment. 152 KD patients were enrolled
- 493 from five clinical centers. After removing 18 incomplete KD cases a final 134 KD
- 494 patients were assigned into test and standard group for trial.

495			
496			
497			
498			
499			
500			
501			
502			
503			
504			
505			
506			
507			
508			
509			
510			

511

512 **Reference**

- 513 1. Burns JC, Glode MP. Kawasaki syndrome. Lancet. 2004;364(9433):533-44. doi:
- 514 10.1016/S0140-6736(04)16814-1. PubMed PMID: 15302199.
- 515 2. Eleftheriou D, Levin M, Shingadia D, Tulloh R, Klein NJ, Brogan PA.
- 516 Management of Kawasaki disease. Arch Dis Child. 2014;99(1):74-83. Epub 20131025.
- 517 doi: 10.1136/archdischild-2012-302841. PubMed PMID: 24162006; PMCID:
- 518 PMC3888612.
- 519 3. Liang CD, Kuo HC, Yang KD, Wang CL, Ko SF. Coronary artery fistula
- associated with Kawasaki disease. Am Heart J. 2009;157(3):584-8. Epub 20090203.
- 521 doi: 10.1016/j.ahj.2008.11.020. PubMed PMID: 19249434.
- 522 4. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC,
- 523 Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME,
- 524 Pallasch TJ, Falace DA, Taubert KA, Committee on Rheumatic Fever E, Kawasaki D,
- 525 Council on Cardiovascular Disease in the Y, American Heart A, American Academy of P.
- 526 Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for
- 527 health professionals from the Committee on Rheumatic Fever, Endocarditis and
- 528 Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart
- 529 Association. Circulation. 2004;110(17):2747-71. doi:
- 530 10.1161/01.CIR.0000145143.19711.78. PubMed PMID: 15505111.
- 531 5. Akagi T, Rose V, Benson LN, Newman A, Freedom RM. Outcome of coronary
- artery aneurysms after Kawasaki disease. J Pediatr. 1992;121(5 Pt 1):689-94. doi:
- 533 10.1016/s0022-3476(05)81894-3. PubMed PMID: 1432415.

Shulman ST, De Inocencio J, Hirsch R. Kawasaki disease. Pediatr Clin North
 Am. 1995;42(5):1205-22. doi: 10.1016/s0031-3955(16)40059-3. PubMed PMID:
 7567192.

537 7. Yu HR, Kuo HC, Sheen JM, Wang L, Lin IC, Wang CL, Yang KD. A unique

538 plasma proteomic profiling with imbalanced fibrinogen cascade in patients with

539 Kawasaki disease. Pediatr Allergy Immunol. 2009;20(7):699-707. Epub 20090112. doi:

540 10.1111/j.1399-3038.2008.00844.x. PubMed PMID: 19170925.

541 8. Wu MT, Hsieh KS, Lin CC, Yang CF, Pan HB. Images in cardiovascular medicine.

542 Evaluation of coronary artery aneurysms in Kawasaki disease by multislice computed

tomographic coronary angiography. Circulation. 2004;110(14):e339. doi:

544 10.1161/01.CIR.0000143374.80173.EF. PubMed PMID: 15466653.

545 9. Weng KP, Ho TY, Chiao YH, Cheng JT, Hsieh KS, Huang SH, Ou SF, Liu KH,

546 Hsu CJ, Lu PJ, Hsiao M, Ger LP. Cytokine genetic polymorphisms and susceptibility to

547 Kawasaki disease in Taiwanese children. Circ J. 2010;74(12):2726-33. Epub 20101030.

548 doi: 10.1253/circj.cj-10-0542. PubMed PMID: 21048327.

10. Weng KP, Hsieh KS, Ho TY, Huang SH, Lai CR, Chiu YT, Huang SC, Lin CC,

550 Hwang YT, Ger LP. IL-1B polymorphism in association with initial intravenous

immunoglobulin treatment failure in Taiwanese children with Kawasaki disease. Circ J.

552 2010;74(3):544-51. Epub 20100118. doi: 10.1253/circj.cj-09-0664. PubMed PMID:

553 **20081319**.

11. Weng KP, Hsieh KS, Hwang YT, Huang SH, Lai TJ, Yuh YS, Hou YY, Lin CC,

555 Huang SC, Chang CK, Lin MW, Ger LP. IL-10 polymorphisms are associated with

corona	ary artery lesions in acute stage of Kawasaki disease. Circ J. 2010;74(5):983-9.
Epub	20100326. doi: 10.1253/circj.cj-09-0801. PubMed PMID: 20339193.
12.	Kuo HC, Yu HR, Juo SH, Yang KD, Wang YS, Liang CD, Chen WC, Chang WP,
Huang	g CF, Lee CP, Lin LY, Liu YC, Guo YC, Chiu CC, Chang WC. CASP3 gene single-
nucleo	otide polymorphism (rs72689236) and Kawasaki disease in Taiwanese children. J
Hum (Genet. 2011;56(2):161-5. Epub 20101216. doi: 10.1038/jhg.2010.154. PubMed
PMID:	21160486.
13.	Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM. Treatment of acute
Kawas	saki disease: aspirin's role in the febrile stage revisited. Pediatrics.
2004;	114(6):e689-93. Epub 20041115. doi: 10.1542/peds.2004-1037. PubMed PMID:
15545	617.
14.	Lee G, Lee SE, Hong YM, Sohn S. Is high-dose aspirin necessary in the acute
phase	of kawasaki disease? Korean Circ J. 2013;43(3):182-6. Epub 20130331. doi:
10.40	70/kcj.2013.43.3.182. PubMed PMID: 23613695; PMCID: PMC3629244.
15.	Saulsbury FT. Comparison of high-dose and low-dose aspirin plus intravenous
immur	noglobulin in the treatment of Kawasaki syndrome. Clin Pediatr (Phila).
2002;4	41(8):597-601. doi: 10.1177/000992280204100807. PubMed PMID: 12403377.
16.	Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH. High-Dose Aspirin is
Assoc	iated with Anemia and Does Not Confer Benefit to Disease Outcomes in
Kawas	saki Disease. PLoS One. 2015;10(12):e0144603. Epub 20151210. doi:
10.13	71/journal.pone.0144603. PubMed PMID: 26658843; PMCID: PMC4686074.
17.	McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M,
Baker	AL, Jackson MA, Takahashi M, Shah PB, Kobayashi T, Wu MH, Saji TT, Pahl E,
	Epub : 12. Huang nucleo Hum (PMID: 13. Kawas 2004; ⁷ 15545 14. phase 10.407 15. immur 2002; ⁴ 16. Assoc Kawas 10.137 17.

American Heart Association Rheumatic Fever E. Kawasaki Disease Committee of the 579 Council on Cardiovascular Disease in the Y, Council on C, Stroke N, Council on 580 Cardiovascular S, Anesthesia, Council on E, Prevention, Diagnosis, Treatment, and 581 Long-Term Management of Kawasaki Disease: A Scientific Statement for Health 582 Professionals From the American Heart Association. Circulation. 2017;135(17):e927-583 e99. Epub 20170329. doi: 10.1161/CIR.0000000000000484. PubMed PMID: 28356445. 584 18. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary 585 artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and 586 587 immunoglobulin treatment. Pediatrics. 1995;96(6):1057-61. PubMed PMID: 7491221. 19. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki 588 disease is highly dependent on gamma globulin dose but independent of salicylate 589 dose. J Pediatr. 1997;131(6):888-93. doi: 10.1016/s0022-3476(97)70038-6. PubMed 590 PMID: 9427895. 591 20. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, 592 Tamura T, Hirose O, Manabe Y, Yokoyama T, et al. Intravenous gamma-globulin for 593 Kawasaki disease. Acta Paediatr Jpn. 1991;33(6):799-804. doi: 10.1111/j.1442-594 595 200x.1991.tb02611.x. PubMed PMID: 1801560. Sanati F, Bagheri M, Eslami S, Khalooei A. Evaluation of high-dose aspirin 21. 596 elimination in the treatment of Kawasaki disease in the incidence of coronary artery 597 598 aneurysm. Ann Pediatr Cardiol. 2021;14(2):146-51. Epub 20210416. doi: 10.4103/apc.APC 206 20. PubMed PMID: 34103852; PMCID: PMC8174624. 599 Chiang MH, Liu HE, Wang JL. Low-dose or no aspirin administration in acute-600 22. 601 phase Kawasaki disease: a meta-analysis and systematic review. Arch Dis Child.

2021;106(7):662-8. Epub 20201110. doi: 10.1136/archdischild-2019-318245. PubMed
PMID: 33172886.

23. Matsubara T, Mason W, Kashani IA, Kligerman M, Burns JC. Gastrointestinal

605 hemorrhage complicating aspirin therapy in acute Kawasaki disease. J Pediatr.

606 1996;128(5 Pt 1):701-3. doi: 10.1016/s0022-3476(96)80140-5. PubMed PMID:

607 8627447.

608 24. Wei CM, Chen HL, Lee PI, Chen CM, Ma CY, Hwu WL. Reye's syndrome

609 developing in an infant on treatment of Kawasaki syndrome. J Paediatr Child Health.

610 2005;41(5-6):303-4. doi: 10.1111/j.1440-1754.2005.00617.x. PubMed PMID: 15953335.

611 25. Lee JH, Hung HY, Huang FY. Kawasaki disease with Reye syndrome: report of

one case. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1992;33(1):67-71. PubMed

613 PMID: 1626454.

26. Wang H, Shimizu C, Bainto E, Hamilton S, Jackson HR, Estrada-Rivadeneyra D,

Kaforou M, Levin M, Pancheri JM, Dummer KB, Tremoulet AH, Burns JC. Subgroups of

616 children with Kawasaki disease: a data-driven cluster analysis. Lancet Child Adolesc

Health. 2023;7(10):697-707. Epub 20230817. doi: 10.1016/S2352-4642(23)00166-9.

618 PubMed PMID: 37598693; PMCID: PMC10756500.

619

620

621

622

623

624

625

626

627

628

Table 1 Baseline Characteristics and Group Distribution of Participants in the

630 **Study**

Variable	Mean ± SD				
	Total (n=134)	Standard Group (n=69)	Test Group (n=65)	_	
Gender, n (%)					
Male	82 (61.2)	43 (62.3)	39 (60. 0)	0.783	
Female	52 (38.8)	26 (37.7)	26 (40.0)		
Age (years)	1.77±1.31	1.85±1.43	1.69±1.17	0.464	
Weight (Kg)	11.14±3.56	11.13±3.56	11.14±3.58	0.986	
Height (cm)	81.83±13.13	81.87±13.85	81.79±12.44	0.969	
Admission (days)	5.12±1.88	4.93±1.86	5.32±1.89	0.224	
White blood cell (WBC,					
1000/µL)	14.19±5.63	15.11±6.21	13.23±4.80	0.053	
Hemoglobin (g/dL)	11.26±1.01	11.13±0.94	11.39±1.07	0.138	
Platelet (1000/µL)	335.20±102.30	350.70±111.20	319.00±90.09	0.074	
CRP (mg/L)	55.47±65.60	68.09±76.66	41.86±48.06	0.021	
GOT (U/L)	95.38±143.70	90.20±120.80	101.30±166.80	0.668	
GPT (U/L)	102.50±127.70	140.70±139.60	100.30±114.80	0.842	
LCMA diameter (mm)	2.20±0.44	2.23±0.48	2.17±0.39	0.380	
LCMA Z score	1.19±0.98	1.26±1.00	1.11±0.96	0.380	
LAD diameter (mm)	1.75±0.42	1.74±0.44	1.76±0.40	0.788	
LAD Z score	0.81±0.74	0.78±0.77	0.84±0.72	0.674	
RAC diameter (mm)	1.91±0.43	1.87±0.44	1.95±0.41	0.281	
RAC Z score	1.16±0.84	1.08±0.90	1.24±0.78	0.279	

631 * *P*<0.05

632 SD: Standard deviation, CRP: C-reactive protein, GOT: Glutamic oxaloacetic

transaminase, GPT: Glutamic pyruvic transaminase, LMCA: Left main coronary artery,

634 RCA: Right coronary artery, LAD: Left anterior descending

635

636 637

638

639

640

- 641
- 642
- 643
- Table 2 Analysis of variance of the effects of treatment in terms of the group,
- 645 time, and their interaction (*Difference between two group, **Difference between the
- 646 three times, ***Interaction effect between time and group)

647

648

649 CRP: C-reactive protein, WBC: White blood cell; GOT: Glutamic oxaloacetic

Variable	Time	I	Mean ± SD		P *	P**	P***
		Standard Group	Test Group	Total			
CRP	Baseline	68.09±76.66	41.86±48.06	55.47±65.60	0.029	<0.001	0.031
	after 6 weeks	1.82±8.78	1.70±7.91	1.76±8.34	0.939		
	after 6 months	N.D.	N.D.	N.D.			
Platelet	Baseline	350.70±111.20	319.00±90.09	335.20±102.30	0.359	0.001	0.123
	after 6 weeks	372.70±114.20	380.80±87.61	376.50±102.10	0.667		
	after 6 months	N.D.	N.D.	N.D.			
WBC	Baseline	15.11±6.21	13.23±4.80	14.19±5.63	0.035	<0.001	0.226
	after 6 weeks	9.15±3.23	8.64±2.54	8.90±2.92	0.336		
	after 6 months	N.D.	N.D.	N.D.			
Hemoglobin	Baseline	11.13±0.94	11.39±1.07	11.26±1.01	0.027	<0.001	0.874
	after 6 weeks	11.86±1.03	12.16±0.98	12.01±1.02	0.102		
	after 6 months	N.D.	N.D.	N.D.			
GOT	Baseline	90.20±120.80	101.30±166.80	95.38±143.70	0.686	<0.001	0.704
	after 6 weeks	38.93±10.37	39.27±7.98	39.09±9.29	0.854		
	after 6 months	N.D.	N.D.	N.D.			
GPT	Baseline	104.70±139.60	100.30±114.80	102.50±127.70	0.869	<0.001	0.842
	after 6 weeks	18.78±9.51	19.19±7.21	18.97±8.46	0.802		
	after 6 months	N.D.	N.D.	N.D.			
LMCA diamete	rBaseline	2.23±0.48	2.17±0.39	2.20±0.44	0.904	<0.001	0.172
	after 6 weeks	2.05±0.45	1.99±0.39	2.02±0.42	0.479		
	after 6 months	1.97±0.38	2.07±0.32	2.02±0.35	0.096		
LAD diameter	Baseline	1.74±0.44	1.76±0.40	1.75±0.42	0.188	<0.001	0.675
	after 6 weeks	1.55±0.39	1.59±0.36	1.57±0.38	0.582		
	after 6 months	1.50±0.39	1.61±0.36	1.56±0.38	0.138		
RCA diameter	Baseline	1.87±0.44	1.95±0.41	1.91±0.43	0.162	0.006	0.827
	after 6 weeks	1.75±0.41	1.77±0.39	1.76±0.40	0.754		
	after 6 months	1.78±0.37	1.85±0.34	1.81±0.36	0.290		

transaminase, GPT: Glutamic pyruvic transaminase, LMCA: Left main coronary artery,
 RCA: Right coronary artery, LAD: Left anterior descending.

652	CAL	Group	Abnormal (Z score>2.5)	Baseline	At 6 th week	At 6 th months	- P
653							
654							
655							
656							
657							
658							
659							
660							
661							
662							
663							
664							
665							
666							
667							
668							
669							
670							
671							
672							
673							
674							
675							
676							
677							
678 679			frequency of abnorr e-combined effect	nal coro	nary arteri	es diameter	' in term of

0	LMCA Test	Yes	4 (6.2)	0 (0.0)	1 (1.5)	0.423
1		No	61 (93.8)	65 (100.0)	64 (98.5)	
2	Standard	Yes	6 (8.7)	2 (2.9)	0 (0.0)	
3		No	63 (91.3)	67 (97.1)	69 (100.0)	
34	P-value		Ref	0.018	0.006	
85	LAD Test	Yes	0 (0.0)	0 (0.0)	0 (0.0)	N.A.
86		No	65 (100.0)	65 (100.0)	65 (100.0)	
37	Standard	Yes	0 (0.0)	0 (0.0)	0 (0.0)	
8		No	69 (100.0)	69 (100.0)	69 (100.0)	
	P-value		Ref	N.A.	N.A.	
39	RCA Test	Yes	4 (6.2)	1 (1.5)	1 (1.5)	0.423
90		No	61 (93.8)	64 (98.5)	64 (98.5)	
91	Standard	Yes	3 (4.3)	1 (1.4)	1 (1.4)	
2		No	66 (95.7)	68 (98.5)	68 (98.5)	
3	P-value		Ref	0.090	0.090	
94	Overall Test	Yes	7 (10.8)	1 (1.5)	2 (3.1)	0.529
5		No	58 (89.2)	64 (98.5)	63 (96.9)	
6	Standard	Yes	9 (13.0)	2 (2.9)	1 (1.4)	
7		No	60 (87.0)	67 (97.1)	68 (98.5)	
8	P-value		Ref	0.002	0.002	
9						
0						
)1	LMCA: Left main coronar	y artery, RCA:	Right corona	ry artery, L	AD: Left an	terior
2	descending.	,	0	,		
3						
4						
5						
)6						
)7						
)8	Table 4 Comparison fre	quency of ab	normal coror	narv arterio	es diamete	r in te
9	groups type and time-tr					

709 groups type and time-treatment effect

CAL	Group	Abnormal (Z score>2.5)	Baseline	At 6 th week	At 6 th months	Ρ
LMCA	Test	Yes	4 (6.2)	0 (0.0)	0 (0.0)	0.225
		No	61 (93.8)	65 (100.0)	65 (100.0)	
	Standard	Yes	6 (8.7)	1 (1.4)	0 (0.0)	
		No	63 (91.3)	68 (98.5)	69 (100.0)	
	P-value		Ref	0.006	0.001	
LAD	Test	Yes	0 (0.0)	0 (0.0)	0 (0.0)	N.A.
		No	65 (100.0)	65 (100.0)	65 (100.0)	
	Standard	Yes	0 (0.0)	0 (0.0)	0 (0.0)	
		No	69 (100.0)	69 (100.0)	69 (100.0)	
	P-value		Ref	N.A.	N.A.	
RCA	Test	Yes	4 (6.2)	1 (1.5)	0 (0.0)	0.184
		No	61 (93.8)	64 (98.5)	65 (100.0)	
	Standard	Yes	3 (4.3)	0 (0.0)	0 (0.0)	
		No	66 (95.7)	69 (100.0)	69 (100.0)	
	P-value		Ref	0.066	0.008	
Overall	Test	Yes	7 (10.8)	1 (1.5)	0 (0.0)	0.423
		No	58 (89.2)	64 (98.5)	65 (100.0)	
	Standard	Yes	9 (13.0)	1 (1.4)	0 (0.0)	
		No	60 (87.0)	68 (98.5)	69 (100.0)	
	P-value		Ref	0.001	<0.001	

710

LMCA: Left main coronary artery, RCA: Right coronary artery, LAD: Left anteriordescending.

713

Figure 1 Consort diagram for patient enrollment.

